Entacapone是有益的波动和non-fluctuating帕金森氏症患者:一个随机,安慰剂对照,双盲,六个月的研究。

文章的细节

引用

复制到剪贴板

布鲁克斯DJ, Sagar H

Entacapone是有益的波动和non-fluctuating帕金森氏症患者:一个随机,安慰剂对照,双盲,六个月的研究。

J神经精神病学Neurosurg。2003年8月,74 (8):1071 - 9。

PubMed ID

12876237 (在PubMed

]

文摘

目的:研究entacapone的影响,特定的外围地表演catechol-O-methyltransferase (COMT的)抑制剂与左旋多巴治疗结合使用,在帕金森病的情况下波动和non-fluctuating对治疗的反应。方法:随机,安慰剂对照,双盲,六个月的研究是在172年波动和128年non-fluctuating病人。200毫克的临床疗效和安全性entacapone每天摄入与每个左旋多巴剂量进行了研究。有效性检查使用家庭日记,统一帕金森病评定量表(UPDRS),并记录日常左旋多巴的剂量。结果:病人比例的每日波动的主要疗效变量与安慰剂比较,显示一个显著增加(p < 0.05)。绝对时间(平均(SD))从9.5(2.5)到10.8(2.4)小时(p < 0.01),每日时间相应减少从7.0(2.6)到5.9(2.5)小时v安慰剂(p < 0.05)。实现这些改进的背景是:每天减少左旋多巴的要求。效果迅速失去entacapone撤军。在non-fluctuating患者中,第二部分主要疗效指标是UPDRS(日常生活的活动;ADL)。 In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients. CONCLUSIONS: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson's disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.

DrugBank数据引用了这篇文章

药物

Entacapone

药物靶点

药物	目标	类	生物	药理作用	行动
Entacapone	儿茶酚O-methyltransferase	蛋白质	人类	是的	抑制剂	细节